RCMI Coordinating Center (RCMI CC) Header Logo

Edna M. Mora Piñero

Concepts (73)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Cell-Derived Microparticles
1
2015
8
0.490
Why?
Biological Specimen Banks
1
2015
28
0.480
Why?
Exosomes
1
2015
124
0.420
Why?
Ascorbic Acid
5
2005
74
0.250
Why?
RNA, Small Interfering
4
2012
436
0.240
Why?
Ovarian Neoplasms
3
2015
406
0.220
Why?
Chitosan
2
2011
52
0.160
Why?
Drug Delivery Systems
3
2011
273
0.160
Why?
Gene Silencing
3
2011
154
0.120
Why?
Receptor, EphB4
1
2015
3
0.120
Why?
Antioxidants
3
2005
439
0.120
Why?
Erythropoietin
1
2015
36
0.120
Why?
Neoplasms
5
2011
1341
0.120
Why?
Breast Neoplasms
3
2015
1679
0.110
Why?
Nanoparticles
2
2011
449
0.110
Why?
Neoplasms, Glandular and Epithelial
1
2012
57
0.090
Why?
Mice, Nude
4
2015
403
0.090
Why?
Lipoproteins, HDL
1
2011
48
0.090
Why?
Hydrogels
1
2011
55
0.080
Why?
Cell Cycle Proteins
1
2012
239
0.080
Why?
Melanoma
1
2011
109
0.080
Why?
Oligopeptides
1
2010
108
0.080
Why?
Gene Expression Regulation, Neoplastic
1
2015
933
0.080
Why?
Animals
6
2015
16695
0.070
Why?
Antineoplastic Agents
4
2011
979
0.060
Why?
Cell Line, Tumor
4
2015
2598
0.060
Why?
Humans
11
2015
42163
0.050
Why?
Orthomolecular Therapy
1
2002
3
0.050
Why?
Copper Sulfate
1
2002
5
0.050
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2015
649
0.040
Why?
Blotting, Western
2
2015
884
0.040
Why?
Mice
4
2012
6490
0.040
Why?
Xenograft Model Antitumor Assays
2
2011
339
0.040
Why?
Female
6
2015
24018
0.030
Why?
Receptors, Erythropoietin
1
2015
6
0.030
Why?
STAT3 Transcription Factor
1
2015
97
0.030
Why?
Infusions, Intravenous
2
2005
55
0.030
Why?
Recombinant Proteins
1
2015
522
0.030
Why?
Injections, Intravenous
2
2004
65
0.030
Why?
Disease Progression
1
2015
661
0.020
Why?
Protein Binding
1
2015
1076
0.020
Why?
Vascular Endothelial Growth Factor A
1
2012
180
0.020
Why?
HCT116 Cells
1
2011
40
0.020
Why?
Neoplasm Invasiveness
1
2012
284
0.020
Why?
Dose-Response Relationship, Drug
2
2005
1112
0.020
Why?
Microspheres
1
2011
49
0.020
Why?
Mice, Inbred C57BL
1
2015
1804
0.020
Why?
Neoplasm Metastasis
1
2011
233
0.020
Why?
Receptors, Cell Surface
1
2010
146
0.020
Why?
Aged, 80 and over
1
2015
2803
0.020
Why?
Aged
2
2015
7982
0.020
Why?
Neoplasm Proteins
1
2010
228
0.020
Why?
RNA, Messenger
1
2012
1265
0.020
Why?
Models, Biological
1
2011
711
0.020
Why?
Middle Aged
2
2015
11819
0.020
Why?
Cell Proliferation
1
2011
1420
0.010
Why?
Palliative Care
1
2005
61
0.010
Why?
Young Adult
1
2015
4936
0.010
Why?
Combined Modality Therapy
1
2005
174
0.010
Why?
Clinical Protocols
1
2003
36
0.010
Why?
Virus Diseases
1
2003
27
0.010
Why?
Bacterial Infections
1
2003
44
0.010
Why?
Clinical Trials as Topic
1
2005
249
0.010
Why?
Anti-Infective Agents
1
2003
74
0.010
Why?
Neoplastic Stem Cells
1
2003
94
0.010
Why?
Drug Resistance, Neoplasm
1
2005
290
0.010
Why?
Pain
1
2005
283
0.010
Why?
Drug Screening Assays, Antitumor
1
2002
147
0.010
Why?
Cell Division
1
2002
314
0.010
Why?
Tumor Cells, Cultured
1
2002
506
0.010
Why?
Treatment Outcome
1
2004
1586
0.010
Why?
Adult
1
2015
13458
0.010
Why?
Male
1
2004
22779
0.000
Why?
Mora Piñero's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (73)
Explore
_
Co-Authors (4)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support